ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook
This article was originally published in The Tan Sheet
Executive Summary
The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial